BCRX(BioCryst Pharmaceuticals, Inc.) · 财务报表

BCRX(BioCryst Pharmaceuticals, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$157.17M$270.83M$331.41M$450.71M$874.84M
毛利润$149.94M$264.42M$326.93M$438.44M$855.76M
营业利润−$177.72M−$148.44M−$103.71M−$2.54M$340.99M
净利润−$184.06M−$247.12M−$226.54M−$88.88M$263.86M
经营现金流−$142.16M−$161.85M−$95.14M−$52.02M$347.37M
自由现金流−$144.54M−$163.20M−$97.31M−$53.14M$344.90M
摊薄每股收益$-1.03$-1.33$-1.18$-0.43$1.21

BioCryst Pharmaceuticals, Inc. BCRX